Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TransMedics Group Inc. shares TMDX, -5.70% jumped more than 40% premarket on Tuesday after the company reported third-quarter results reflecting growing demand for its organ-transplant services and raised its full-year revenue outlook.

TransMedics' stock pops after organ-transplant company's ‘blockbuster' third-quarter results

TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2023 Earnings Call Transcript November 6, 2023 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Ryan Daniels - William Blair Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics Group, Inc. (TMDX) Q3 2023 Earnings Call Transcript

ANDOVER, Mass. , Nov. 6, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023.

TransMedics Reports Third Quarter 2023 Financial Results

Brookfield Infrastructure Partners L.P.

Brookfield Infrastructure

Mastercard

Roku

This holiday season features deals on growth, value, and income stocks. Cyclical downturns are affecting multiple industries.

5 Top Stocks for November

Brookfield Renewable Partners

Vertex Pharmaceuticals

Vertex Pharmaceuticals' pipeline should enable the biotech to deliver explosive growth. TransMedics Group is disrupting a huge -- and rapidly growing -- market.

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade

ANDOVER, Mass. , Oct. 23, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2023 after market close on Monday, November 6, 2023.

TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023

TransMedic's Organ Care System is revolutionizing the organ transplant industry. However, the company's acquisition of a charter flight operator has worried the market.

1 Unstoppable Growth Stock to Buy in 2023 and Beyond

Today, we put the focus on TransMedics Group, Inc., a healthcare company focused on transforming the organ transport and transplant industry. The company recently acquired Summit Aviation, a charter flight operator, to enhance its logistical capabilities for organ transplantation. TransMedics reported strong second quarter results, with revenues exceeding expectations and an improved net loss compared to the previous year.

TransMedics Group: A Company In Flux

TransMedics is a medical tech company focused on organ transplants in the US. TMDX looks set to be a key enabler in raising the transplant volumes carried out in the country. TMDX has experienced strong topline growth and has the potential for continued growth, but short-term risks and technical considerations warrant some caution.

TransMedics: Transforming The Landscape, But No Rush To Buy

Hospitals and transplant centers increasingly rely on TransMedics Group to retrieve donated hearts, lungs, and livers, and deliver them long distances. At the heart of TransMedic Group's operation is a portable device that pumps warm blood through donated organs to preserve their viability.

Down More Than 50% Since July, This Incredible Growth Stock Is a Screaming Buy on the Dip

Intuitive Surgical

Medpace Holdings

Intuitive Surgical's 80% market share and razor-and-blade model deserve a premium valuation. TransMedics is not only an easy stock to root for but is in hyper-growth mode and nearing profitability.

3 Best Stocks to Buy With $300 Right Now

Humana

Johnson & Johnson

In the ever-evolving landscape of investing, the spotlight is on the top healthcare stocks to buy on the dip. The healthcare sector is highly known for its robust resilience and incredible growth potential.

Buy the Dip: 3 Healthcare Stocks to Snag Now for Supercharged Gains

Insulet

Shockwave Medical

The healthcare sector has underperformed this year, with the Health Care Select Sector SPDR (NYSEARCA: XLV ) down 1%. After a disappointing year-to-date performance, it's time to consider some top healthcare stock picks.

The 3 Most Promising Healthcare Stocks to Own Now

Paycom Software

SoFi Technologies

SoFi's banking unit provides it with incredible growth and improved profitability. TransMedics is reinventing how the organ donation system works with its one-of-a-kind platform.

3 Top Growth Stocks to Buy Right Now

ANDOVER, Mass. , Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York.

TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.

TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant

ANDOVER, Mass. , Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the closing of its previously announced acquisition of Summit Aviation, a premier U.S. charter flight operator.

TransMedics Completes Acquisition of Summit Aviation

TransMedics Group, Inc. posted exceptional Q2 results with a 156% YoY increase in revenues, reaching the highest second-quarter turnover in the company's history. The company aims to have 100% availability over the U.S. continent by mid-next year, with plans to acquire 10-15 aircrafts for its air logistics operations. Net-net, reiterate buy, revising the price objective to $150/share.

TransMedics: Aircraft Additions Bring Immense Gross-Value Add, Reiterate Buy

DigitalOcean Holdings

The modest sum of $200 is more than enough to buy shares of two exceptional growth stocks right now. TransMedics Group is singlehandedly improving an outdated system for managing donated transplant organs.

2 Unstoppable Growth Stocks You Can Buy With $200 Right Now

The company's Organ Care System is used to improve transplant outcomes for heart, liver, and lung transplants. It improved revenue and trimmed its losses in the quarter, year over year.

Why Shares of TransMedics Group Are Falling Friday

TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Bill Plovanic - Canaccord Allen Gong - JPMorgan Suraj Kalia - Oppenheimer Ryan Daniels - William Blair Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics Group, Inc. (TMDX) Q2 2023 Earnings Call Transcript

TransMedics (TMDX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.41 per share a year ago.

TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates

ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2023.

TransMedics Reports Second Quarter 2023 Financial Results

NORTHBROOK, Ill. , Aug. 2, 2023 /PRNewswire/ -- Bridge to Life Ltd.

Bridge to Life Divests Certain Assets to TransMedics

ANDOVER, Mass. , Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that is has acquired from Bridge to Life Ltd.

News for Transmedics Group Inc Stock (TMDX)